Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 10/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186622 | 0.86 | CA12 (0.45) | LOXL2CA12CA1CA9MTNR1A | |
| SCHEMBL30920584 | 0.77 | LOXL2 (0.76) | LOXL2MTNR1AMTNR1BCA2 | |
| SCHEMBL23501875 | 0.77 | LOXL2 (0.76) | LOXL2MTNR1AMTNR1BCA2 | |
| SCHEMBL4190788 | 0.76 | CA12 (0.46) | CA12CA1CA9MTNR1AMTNR1B | |
| SCHEMBL1621740 | 0.75 | CA12 (0.45) | CA12CA1CA9PREPCA2 | |
| SCHEMBL29952094 | 0.75 | CA12 (0.45) | CA12CA1CA9PREPCA2 | |
| SCHEMBL4192383 | 0.74 | EIF4A3 (0.49) | CA12CA1CA9 | |
| SCHEMBL31663239 | 0.73 | LOXL2 (0.36) | LOXL2CA12CA1CA9CA2 | |
| SCHEMBL3017521 | 0.72 | XDH (0.47) | CA12CA1CA9 | |
| SCHEMBL27247673 | 0.72 | LOXL2 (0.42) | LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090060968-A1 | INHIBITORS OF PHOSPHATASES | SAUNDERS JEFFREY O | 2009-03-05 | — | — | US | disclosed |
| US-20090060968-A1 | INHIBITORS OF PHOSPHATASES | SAUNDERS JEFFREY O | 2009-03-05 | — | — | US | disclosed |
| US-7439249-B2 | Inhibitors of phosphatases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439249-B2 | Inhibitors of phosphatases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1583747-A2 | INHIBITORS OF PHOSPHATASES | Vertex Pharmaceuticals Incorporated (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040186116-A1 | such as 2-(7-acetylamino-1-furano-2-ylmethyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-succinic acid; for treatment of autoimmune diseases, proliferative diseases, angiogenic disorders, and/or cancers; catheters, prosthetics | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| WO-2004060878-A2 | INHIBITORS OF PHOSPHATASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060968-A1 | INHIBITORS OF PHOSPHATASES | PPM1G, PPM1A, PPM1F | LOXL2 2519/4885CA12 3046/4885CA1 2064/4885 |
| US-20040186116-A1 | such as 2-(7-acetylamino-1-furano-2-ylmethyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-succinic acid; for treatment of autoimmune diseases, proliferative diseases, angiogenic disorders, and/or cancers; catheters, prosthetics | CD47, FGF1, FGF2 | LOXL2 2429/4885CA12 202/4885CA1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.